» Articles » PMID: 38866775

Structural Basis for Urate Recognition and Apigenin Inhibition of Human GLUT9

Overview
Journal Nat Commun
Specialty Biology
Date 2024 Jun 12
PMID 38866775
Authors
Affiliations
Soon will be listed here.
Abstract

Urate, the physiological form of uric acid and a potent antioxidant in serum, plays a pivotal role in scavenging reactive oxygen species. Yet excessive accumulation of urate, known as hyperuricemia, is the primary risk factor for the development of gout. The high-capacity urate transporter GLUT9 represents a promising target for gout treatment. Here, we present cryo-electron microscopy structures of human GLUT9 in complex with urate or its inhibitor apigenin at overall resolutions of 3.5 Å and 3.3 Å, respectively. In both structures, GLUT9 exhibits an inward open conformation, wherein the substrate binding pocket faces the intracellular side. These structures unveil the molecular basis for GLUT9's substrate preference of urate over glucose, and show that apigenin acts as a competitive inhibitor by occupying the substrate binding site. Our findings provide critical information for the development of specific inhibitors targeting GLUT9 as potential therapeutics for gout and hyperuricemia.

Citing Articles

In Slico Screening and In Vitro Identification of Hyperuricemia-Inhibiting Peptides from .

Xu Z, Gan M, Guan W, Tian F, Wang Y, Zhang J Foods. 2025; 14(3).

PMID: 39942117 PMC: 11817512. DOI: 10.3390/foods14030524.


Structural basis of disease mutation and substrate recognition by the human SLC2A9 transporter.

Khandelwal N, Gupta M, Kumar P, Balasubramani S, Echeverria I, Stroud R Proc Natl Acad Sci U S A. 2025; 122(7):e2418282122.

PMID: 39937868 PMC: 11848319. DOI: 10.1073/pnas.2418282122.


A comprehensive analysis of trends in the burden of gout in China and globally from 1990 to 2021.

Xie S, Xiao H, Xu L, Li G, Zhang F, Luo M Sci Rep. 2025; 15(1):3310.

PMID: 39865102 PMC: 11770106. DOI: 10.1038/s41598-025-86090-z.


Transport mechanism and structural pharmacology of human urate transporter URAT1.

Dai Y, Lee C Cell Res. 2024; 34(11):776-787.

PMID: 39245778 PMC: 11528023. DOI: 10.1038/s41422-024-01023-1.

References
1.
Dehlin M, Jacobsson L, Roddy E . Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020; 16(7):380-390. DOI: 10.1038/s41584-020-0441-1. View

2.
Wright A, Rudan I, Hastie N, Campbell H . A 'complexity' of urate transporters. Kidney Int. 2010; 78(5):446-52. DOI: 10.1038/ki.2010.206. View

3.
So A, Thorens B . Uric acid transport and disease. J Clin Invest. 2010; 120(6):1791-9. PMC: 2877959. DOI: 10.1172/JCI42344. View

4.
Matsuda T, Cepko C . Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc Natl Acad Sci U S A. 2003; 101(1):16-22. PMC: 314130. DOI: 10.1073/pnas.2235688100. View

5.
Danve A, Sehra S, Neogi T . Role of diet in hyperuricemia and gout. Best Pract Res Clin Rheumatol. 2021; 35(4):101723. PMC: 8678356. DOI: 10.1016/j.berh.2021.101723. View